{"id":7361,"date":"2024-07-06T23:50:19","date_gmt":"2024-07-06T23:50:19","guid":{"rendered":"https:\/\/demo5.dedicatedhost247.com\/zexo\/this-etf-is-trying-to-satisfy-appetites-for-weight-loss-stocks\/"},"modified":"2024-07-06T23:50:19","modified_gmt":"2024-07-06T23:50:19","slug":"this-etf-is-trying-to-satisfy-appetites-for-weight-loss-stocks","status":"publish","type":"post","link":"https:\/\/demo5.dedicatedhost247.com\/zexo\/this-etf-is-trying-to-satisfy-appetites-for-weight-loss-stocks\/","title":{"rendered":"This ETF is trying to satisfy appetites for weight loss stocks"},"content":{"rendered":"


\n<\/p>\n

<\/p>\n
\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n

Tema ETFs has been capitalizing on the risk appetite for weight loss stocks.<\/p>\n

It is behind the GLP-1, Obesity & Cardiometabolic ETF (HRTS)<\/a>, which is up 26% since its inception last November.<\/p>\n

The firm’s founder and CEO Maurits Pot thinks the winning weight loss trade isn’t based on just hype.<\/p>\n

“The companies we track and the companies we invest in are looking not just at a weight loss approach, but also other approaches,” Pot told CNBC’s “ETF Edge<\/a>” on Monday. “We could see a world where the majority of the world’s population takes a GLP-1, not just for weight loss, but for other diseases.”<\/p>\n

His top holdings include Mounjaro manufacturer Eli Lilly and Ozempic and Wegovy maker Novo Nordisk. Eli Lilly<\/a>